Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer's DiseaseGlobeNewsWire • 06/28/23
Cognition Therapeutics to Host Call and Webcast to Discuss Topline Results from CT1812 Phase 2 SEQUEL Study on June 28, 2023GlobeNewsWire • 06/27/23
Cognition Therapeutics Invited to Participate on Panel During Cantor Fitzgerald Brain Week 2023 on Novel Alzheimer's Disease ApproachesGlobeNewsWire • 06/20/23
Cognition Therapeutics Continues Investor Engagement in June with Presentations at World Medical Innovation and Longwood Healthcare Leaders ConferencesGlobeNewsWire • 06/02/23
Cognition Therapeutics Latest Episode of “Conversations” Podcast Features Biomarker Experts from Gothenburg University, Emory and Amsterdam UMCGlobeNewsWire • 05/23/23
Cognition Therapeutics Publishes Clinical Evidence that CT1812 Displaces Aβ Oligomers from Binding to Neuronal Synapses in Alzheimer's DiseaseGlobeNewsWire • 05/18/23
Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/04/23
Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial OfficerGlobeNewsWire • 05/01/23
Cognition Therapeutics to Present Analysis Showing Impact of CT1812 on Pathways Implicated in Dry Age-related Macular Degeneration at ARVO 2023GlobeNewsWire • 04/19/23
Cognition Therapeutics Announces New Scientific Publication on Therapeutic Potential of Targeting Sigma-2 Receptor for Age-related Degenerative DiseasesGlobeNewsWire • 04/12/23
Cognition Therapeutics Presents Proteomic Biomarker Data Demonstrating Prominent Effects of CT1812 in Altering Underlying Alzheimer's Disease ProcessesGlobeNewsWire • 03/28/23
Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 03/23/23
Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer's Disease at AD/PD 2023GlobeNewsWire • 03/21/23
UPDATE – Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 ResultsGlobeNewsWire • 03/16/23
Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMDGlobeNewsWire • 03/15/23
Cognition Therapeutics to Present at the 33rd Annual Oppenheimer & Co Annual Healthcare ConferenceGlobeNewsWire • 03/07/23
Cognition Therapeutics Announces New Episode of “Conversations” Podcast: What if it's not Alzheimer's? The Caregiver's Perspective on Lewy Body DementiaGlobeNewsWire • 02/21/23
Cognition Therapeutics Completes Enrollment of CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer's DiseaseGlobeNewsWire • 02/09/23
These 10 Stocks Had the Most Insider Buying Activity During the December Quarter24/7 Wall Street • 01/10/23
Cognition Therapeutics Announces New “Conversations” Podcast Episode on Key Insights from Recent Clinical Trials in Alzheimer's DiseaseGlobeNewsWire • 12/22/22
Cognition Therapeutics Announces Participation in Sachs 6th Annual Neuroscience Forum, Biotech Showcase, and BIO Partnering @ JPM During "J.P. Morgan Week 2023"GlobeNewsWire • 12/21/22
First Participant Dosed in Europe as Cognition Therapeutics Expand Phase 2 Alzheimer's Disease Clinical Trial of Oral CT1812GlobeNewsWire • 12/15/22
Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMDGlobeNewsWire • 12/01/22